Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 23Carcinoma, Non-Small-Cell Lung 15Prostatic Neoplasms 14Stomach Neoplasms 12Colorectal Neoplasms 12Breast Neoplasms 12Pancreatic Neoplasms 11Leukemia, Myeloid, Acute 10Neoplasm Metastasis 9Lung Neoplasms 9Hematologic Neoplasms 9Head and Neck Neoplasms 9Endometrial Neoplasms 9Carcinoma, Hepatocellular 9Squamous Cell Carcinoma of Head and Neck 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Ovarian Neoplasms 8Myasthenia Gravis 7Melanoma 7Uterine Cervical Neoplasms 6Recurrence 6Rectal Neoplasms 6Neoplasms by Site 6Neoplasms by Histologic Type 6Lymphoma 6Leukemia 6Urinary Bladder Neoplasms 5Neoplasms, Plasma Cell 5Infections 5Colonic Neoplasms 5

Interventions

fasudil 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Recruiting × Prostate CA × Clear all
NCT06861192 2025-11-18

Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer

Zhongda Hospital

Phase 2/3 Recruiting
83 enrolled
Genitourinary

Prostate CA

Data powered by HemOnc (CC BY 4.0) Colophon âš¡